Skip to main content
Erschienen in: CEN Case Reports 2/2019

30.01.2019 | Case Report

A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes

verfasst von: Tamayo Kato, Yasuyuki Ushiogi, Hitoshi Yokoyama, Shigeo Hara, Akira Matsunaga, Eri Muso, Takao Saito

Erschienen in: CEN Case Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

A 47-year-old Japanese man with mild proteinuria was treated with an ACE inhibitor and antiplatelet agent for 7 years. However, urinary protein levels increased and renal biopsy was performed. Eight out of 20 glomeruli showed global or segmental sclerosis with foamy changes or bubbles, but with a different appearance to typical foam cells or lipoprotein thrombi. “Spike” formation, as observed in membranous nephropathy (MN), was segmentally detected in methenamine silver-stained sections. In an immunofluorescence study, weak linear patterns for IgG and scanty deposits for C3 were observed in glomeruli, but were not specific for immunogenetic MN. An electron microscopy study showed highly dense deposits in the subepithelial, subendothelial, and mesangial areas, in which microbubbles appeared under a higher magnification. Since this case exhibited hypertriglyceridemia and cholesterolemia with high serum apolipoprotein E (apoE) clinically and homozygous apoE2/2 by apoE phenotype and genotype analyses, apoE2 homozygote glomerulopathy was diagnosed and various lipid-lowering agents, e.g., probucol, fenofibrate, and ezetimibe, were administered. However, renal dysfunction gradually developed and peritoneal dialysis was initiated 11 years after the diagnosis. ApoE Toyonaka (Ser197Cys) and homozygous E2/2 were recently identified by direct DNA sequencing. Therefore, non-immune MN-like lesions may develop with the combination of these apoE mutations.
Literatur
1.
Zurück zum Zitat Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem. 2011;48:498–515.CrossRefPubMed Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem. 2011;48:498–515.CrossRefPubMed
2.
Zurück zum Zitat Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;15:359–65.CrossRefPubMedPubMedCentral Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;15:359–65.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.CrossRefPubMed Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.CrossRefPubMed
4.
Zurück zum Zitat Kawanishi K, Sawada A, Ochi A, Moriyama T, Mitobe M, Mochizuki T, Honda K, Oda H, Nishikawa T, Nitta K. Glomerulopathy with homozygous apolipoprotein E2: a report of three cases and review of the literature. Case Rep Nephrol Urol. 2013;3:128–35.CrossRefPubMedPubMedCentral Kawanishi K, Sawada A, Ochi A, Moriyama T, Mitobe M, Mochizuki T, Honda K, Oda H, Nishikawa T, Nitta K. Glomerulopathy with homozygous apolipoprotein E2: a report of three cases and review of the literature. Case Rep Nephrol Urol. 2013;3:128–35.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Fukunaga M, Nagahama K, Aoki M, Shimizu A, Hara s, Matsunaga A, Muso E, Saito T. Membranous nephropathy-like apolipoprotein E deposition disease with apolipoprotein E Toyonaka (Ser197Cys) and a homozygous apolipoprotein E2/2. Case Rep Nephrol Dial. 2018;8:45–55.CrossRefPubMedPubMedCentral Fukunaga M, Nagahama K, Aoki M, Shimizu A, Hara s, Matsunaga A, Muso E, Saito T. Membranous nephropathy-like apolipoprotein E deposition disease with apolipoprotein E Toyonaka (Ser197Cys) and a homozygous apolipoprotein E2/2. Case Rep Nephrol Dial. 2018;8:45–55.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hirashima H, Komiya T, Toriu N, Hara S, Matsunaga A, Saito T, Muso E. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apoE Toyonaka. Clin Nephrol Case Stud. 2018;6:45–51.CrossRefPubMedPubMedCentral Hirashima H, Komiya T, Toriu N, Hara S, Matsunaga A, Saito T, Muso E. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apoE Toyonaka. Clin Nephrol Case Stud. 2018;6:45–51.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, Hayasaka K, Kotake H, Midorikawa H, Sekikawa A, Hara S, Abe K, Toyota T, Jingami H, Nakamura H, Sasaki J. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMed Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, Hayasaka K, Kotake H, Midorikawa H, Sekikawa A, Hara S, Abe K, Toyota T, Jingami H, Nakamura H, Sasaki J. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMed
8.
Zurück zum Zitat Matsunaga A, Sasaki J, Komatsu T, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.CrossRefPubMed Matsunaga A, Sasaki J, Komatsu T, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.CrossRefPubMed
9.
Zurück zum Zitat Kodera H, Mizutani Y, Sugiyama S, Miyata T, Ehara T, Matsunaga A, Saito T. A case of lipoprotein glomerulopathy with apoE Chicago and apoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7:112–20.CrossRefPubMedPubMedCentral Kodera H, Mizutani Y, Sugiyama S, Miyata T, Ehara T, Matsunaga A, Saito T. A case of lipoprotein glomerulopathy with apoE Chicago and apoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial. 2017;7:112–20.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Narayanaswami V, Szeto SS, Ryan RO. Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3. J Biol Chem. 2001;276:37853–60.PubMed Narayanaswami V, Szeto SS, Ryan RO. Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3. J Biol Chem. 2001;276:37853–60.PubMed
11.
Zurück zum Zitat Masoodi TA, Al Shammari SA, Al-Muammar MN, Alhamdan AA. Screening and evaluation of deleterious SNPs in APOE gene of Alzheimer’s disease. Neurol Res Int. 2012;2012:480609.CrossRefPubMedPubMedCentral Masoodi TA, Al Shammari SA, Al-Muammar MN, Alhamdan AA. Screening and evaluation of deleterious SNPs in APOE gene of Alzheimer’s disease. Neurol Res Int. 2012;2012:480609.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, Phillips MC, Lund-Katz S. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res. 2002;43:1688–700.CrossRefPubMed Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, Phillips MC, Lund-Katz S. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res. 2002;43:1688–700.CrossRefPubMed
13.
Zurück zum Zitat Zhang Y, Vasudevan S, Sojitrawala R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG, Weisgraber K, Li Q, Wang J. A monomeric, biologically active, full-length human apolipoprotein E. Biochemistry. 2007;46:10722–32.CrossRefPubMed Zhang Y, Vasudevan S, Sojitrawala R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG, Weisgraber K, Li Q, Wang J. A monomeric, biologically active, full-length human apolipoprotein E. Biochemistry. 2007;46:10722–32.CrossRefPubMed
14.
Zurück zum Zitat Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011;108:14813–8.CrossRefPubMed Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011;108:14813–8.CrossRefPubMed
15.
Zurück zum Zitat Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–30.CrossRefPubMed Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–30.CrossRefPubMed
16.
Zurück zum Zitat Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Arakawa M, Gejyo F. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int. 2001;59:1911–8.CrossRefPubMed Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Arakawa M, Gejyo F. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int. 2001;59:1911–8.CrossRefPubMed
17.
Zurück zum Zitat Saito T, Matsunaga A, Ito K, Nakashima H. Topics in lipoprotein glomerulopathy: an overview. Clin Exp Nephrol. 2014;18:214–7.CrossRefPubMed Saito T, Matsunaga A, Ito K, Nakashima H. Topics in lipoprotein glomerulopathy: an overview. Clin Exp Nephrol. 2014;18:214–7.CrossRefPubMed
Metadaten
Titel
A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes
verfasst von
Tamayo Kato
Yasuyuki Ushiogi
Hitoshi Yokoyama
Shigeo Hara
Akira Matsunaga
Eri Muso
Takao Saito
Publikationsdatum
30.01.2019
Verlag
Springer Singapore
Erschienen in
CEN Case Reports / Ausgabe 2/2019
Elektronische ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-019-00380-w

Weitere Artikel der Ausgabe 2/2019

CEN Case Reports 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.